In Brief: FDA blood glucose monitor guidance
This article was originally published in The Gray Sheet
Executive Summary
FDA blood glucose monitor guidance: Agency planning to form working group comprised of FDA, industry reps, patients, nurse educators and other healthcare professionals to gain input on ways to improve the agency's revised guidance on self-monitoring blood glucose monitors. FDA's Clinical Chemistry and Clinical Toxicology Panel recommended greater cooperation between the various parties at its March 20-21 meeting, which was held to discuss ways to minimize problems related to the devices ("The Gray Sheet" March 31, p. 12). The widely used products generate the most adverse event reports of all in vitro diagnostics...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.